FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1976844172> ?p ?o ?g. }

• W1976844172 endingPage "2098" @default.
• W1976844172 startingPage "2091" @default.
• W1976844172 abstract "Aim To assess the activity and safety of non-pegylated liposomal doxorubicin (Myocet®) in combination with docetaxel and trastuzumab as first-line treatment of patients with HER-2/neu-positive metastatic breast cancer (MBC). Patients and methods The maximum tolerated dose of the combination was defined in the phase I part of the study. In the phase II part, 45 HER-2/neu-positive MBC patients were enrolled to receive 6–8 cycles of Myocet® 50 mg/m2 (day 1), docetaxel 30 mg/m2 (days 2 and 9) plus trastuzumab (day 2, 4 mg/kg followed by 2 mg/kg/week) every 21 d until unacceptable toxicity or progression occurred. Objective response (primary end-point) and treatment tolerability were assessed according to World Health Organisation criteria. Cardiotoxicity was defined as signs and/or symptoms of congestive heart failure and/or a decrease in left ventricular ejection fraction (LVEF). Results The overall response rate was 55.6% (complete response 8.9%, partial response 46.7%), with a median time-to-progression of 10.9 months (C.I. 8.7–15.0). Median overall survival was not reached. The most frequent grade 3–4 adverse events were granulocytopaenia (60.0%), leukocytopenia (43.2%) and alopecia (35.6%). Grade 3–4 diarrhoea, pain, oral and skin toxicity (4.4%, each) and nausea/vomiting, thrombocytopenia and elevated alkaline phosphatase (2.2%, each) were also reported. In 2 patients LVEF fell to <50%, with a decrease from baseline >15%. LVEF median values remained stable from baseline to the end of the study (60%). Conclusions The combination of Myocet®, docetaxel and trastuzumab is safe and shows promising activity as first-line treatment of HER-2-positive MBC." @default.
• W1976844172 created "2016-06-24" @default.
• W1976844172 creator A5001899541 @default.
• W1976844172 creator A5001955439 @default.
• W1976844172 creator A5008135397 @default.
• W1976844172 creator A5010937667 @default.
• W1976844172 creator A5012446712 @default.
• W1976844172 creator A5013748999 @default.
• W1976844172 creator A5023921586 @default.
• W1976844172 creator A5031521140 @default.
• W1976844172 creator A5044655947 @default.
• W1976844172 creator A5056559714 @default.
• W1976844172 creator A5058172205 @default.
• W1976844172 creator A5073516776 @default.
• W1976844172 creator A5075055655 @default.
• W1976844172 creator A5091182210 @default.
• W1976844172 date "2011-09-01" @default.
• W1976844172 modified "2023-10-02" @default.
• W1976844172 title "A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer" @default.
• W1976844172 cites W1940754997 @default.
• W1976844172 cites W1973420828 @default.
• W1976844172 cites W1987593270 @default.
• W1976844172 cites W2008571023 @default.
• W1976844172 cites W2025689023 @default.
• W1976844172 cites W2029667659 @default.
• W1976844172 cites W2036045878 @default.
• W1976844172 cites W2045324973 @default.
• W1976844172 cites W2070377409 @default.
• W1976844172 cites W2070825008 @default.
• W1976844172 cites W2086000565 @default.
• W1976844172 cites W2096593771 @default.
• W1976844172 cites W2100014422 @default.
• W1976844172 cites W2101321780 @default.
• W1976844172 cites W2112221008 @default.
• W1976844172 cites W2128941584 @default.
• W1976844172 cites W2141056749 @default.
• W1976844172 cites W2149773268 @default.
• W1976844172 cites W2169073956 @default.
• W1976844172 cites W2318605753 @default.
• W1976844172 doi "https://doi.org/10.1016/j.ejca.2011.05.005" @default.
• W1976844172 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21665463" @default.
• W1976844172 hasPublicationYear "2011" @default.
• W1976844172 type Work @default.
• W1976844172 sameAs 1976844172 @default.
• W1976844172 citedByCount "26" @default.
• W1976844172 countsByYear W19768441722012 @default.
• W1976844172 countsByYear W19768441722013 @default.
• W1976844172 countsByYear W19768441722014 @default.
• W1976844172 countsByYear W19768441722015 @default.
• W1976844172 countsByYear W19768441722016 @default.
• W1976844172 countsByYear W19768441722017 @default.
• W1976844172 countsByYear W19768441722018 @default.
• W1976844172 countsByYear W19768441722019 @default.
• W1976844172 countsByYear W19768441722020 @default.
• W1976844172 countsByYear W19768441722021 @default.
• W1976844172 countsByYear W19768441722022 @default.
• W1976844172 crossrefType "journal-article" @default.
• W1976844172 hasAuthorship W1976844172A5001899541 @default.
• W1976844172 hasAuthorship W1976844172A5001955439 @default.
• W1976844172 hasAuthorship W1976844172A5008135397 @default.
• W1976844172 hasAuthorship W1976844172A5010937667 @default.
• W1976844172 hasAuthorship W1976844172A5012446712 @default.
• W1976844172 hasAuthorship W1976844172A5013748999 @default.
• W1976844172 hasAuthorship W1976844172A5023921586 @default.
• W1976844172 hasAuthorship W1976844172A5031521140 @default.
• W1976844172 hasAuthorship W1976844172A5044655947 @default.
• W1976844172 hasAuthorship W1976844172A5056559714 @default.
• W1976844172 hasAuthorship W1976844172A5058172205 @default.
• W1976844172 hasAuthorship W1976844172A5073516776 @default.
• W1976844172 hasAuthorship W1976844172A5075055655 @default.
• W1976844172 hasAuthorship W1976844172A5091182210 @default.
• W1976844172 hasConcept C121608353 @default.
• W1976844172 hasConcept C126322002 @default.
• W1976844172 hasConcept C141071460 @default.
• W1976844172 hasConcept C143998085 @default.
• W1976844172 hasConcept C197934379 @default.
• W1976844172 hasConcept C203092338 @default.
• W1976844172 hasConcept C2775930923 @default.
• W1976844172 hasConcept C2776694085 @default.
• W1976844172 hasConcept C2778198053 @default.
• W1976844172 hasConcept C2778233292 @default.
• W1976844172 hasConcept C2778375690 @default.
• W1976844172 hasConcept C2779786085 @default.
• W1976844172 hasConcept C2780580376 @default.
• W1976844172 hasConcept C2781190966 @default.
• W1976844172 hasConcept C2909463153 @default.
• W1976844172 hasConcept C31760486 @default.
• W1976844172 hasConcept C530470458 @default.
• W1976844172 hasConcept C535046627 @default.
• W1976844172 hasConcept C71924100 @default.
• W1976844172 hasConcept C78085059 @default.
• W1976844172 hasConcept C90924648 @default.
• W1976844172 hasConceptScore W1976844172C121608353 @default.
• W1976844172 hasConceptScore W1976844172C126322002 @default.
• W1976844172 hasConceptScore W1976844172C141071460 @default.
• W1976844172 hasConceptScore W1976844172C143998085 @default.
• W1976844172 hasConceptScore W1976844172C197934379 @default.
• W1976844172 hasConceptScore W1976844172C203092338 @default.

• next